Patents by Inventor Lynne Ann Isopi

Lynne Ann Isopi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS
    Publication number: 20240131144
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Application
    Filed: December 6, 2023
    Publication date: April 25, 2024
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Morrisa Jones, Justin Stanbro, Akhilesh Bhambhani, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
  • Formulations of dengue virus vaccine compositions
    Patent number: 11883480
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Grant
    Filed: July 26, 2022
    Date of Patent: January 30, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
  • STABLE FORMULATIONS OF CYTOMEGALOVIRUS
    Publication number: 20230277654
    Abstract: The present invention relates to stable formulations of a cytomegalovirus (CMV) comprising for example, a genetically modified CMV that is conditionally replication defective, a buffer, alkali or alkaline salt, a sugar, a cellulose derivative and optionally a polyol.
    Type: Application
    Filed: November 30, 2022
    Publication date: September 7, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Muneeswara Babu Medi, Harrison Bradford Davis, Lorenzo H. Chen, Lynne Ann Isopi, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler
  • FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS
    Publication number: 20230061673
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live, attenuated dengue virus or live, attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Application
    Filed: July 26, 2022
    Publication date: March 2, 2023
    Applicant: Merck Sharp & Dohme LLC
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Morrisa Jones, Justin Stanbro, Akhilesh Bhambhani, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi
  • STABLE FORMULATIONS OF CYTOMEGALOVIRUS
    Publication number: 20210299247
    Abstract: The present invention relates to stable formulations of a cytomegalovirus (CMV) comprising for example, a genetically modified CMV that is conditionally replication defective, a buffer, alkali or alkaline salt, a sugar, a cellulose derivative and optionally a polyol.
    Type: Application
    Filed: October 29, 2018
    Publication date: September 30, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Muneeswara Babu Medi, Harrison Bradford Davis, Lorenzo H. Chen, Lynne Ann Isopi, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler
  • FORMULATIONS OF DENGUE VIRUS VACCINE COMPOSITIONS
    Publication number: 20200390877
    Abstract: The present invention relates to formulations of dengue virus vaccine comprising at least one live attenuated dengue virus or live attenuated chimeric flavivirus, a buffer, a sugar, a cellulose derivative, a glycol or sugar alcohol, optionally an alkali or alkaline salt and an amino acid; and formulations of dengue virus vaccine comprising at least one live attenuated dengue virus or live attenuated chimeric flavivirus, a buffer, a sugar of at least 150 mg/ml, a carrier, and optionally an alkali or alkaline salt and an amino acid.
    Type: Application
    Filed: December 3, 2018
    Publication date: December 17, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael S. Ryan, Sherrie-Ann P. Martin, Morrisa Jones, Justin Stanbro, Akhilesh Bhambhani, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler, Lynne Ann Isopi